This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the US I am a US resident I am a patient outside the US
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

Patient FAQ
Tips For Taking TASIGNA
TASIGNA Daily Planner

PATIENT SUPPORT MATERIALS

Information is available to help your patients adjust to their Ph+ CML and incorporate TASIGNA into their everyday lives

A diagnosis of Ph+ CML can require an adjustment for many patients. Novartis Oncology has provided a variety of tools that you can walk through with your patients or use as a guide for talking to them about their disease and treatment.

In this section you will find:


Reference:
1. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356.

TASIGNA Interactive Game

Use the interactive daily planner to find the best time to fit TASIGNA into your patients' schedules

To see how TASIGNA is an optimized BCR-ABL inhibitor that was designed to improve on imatinib, go to TASIGNA mechanism of action1